Clinical trials: Patients with Advanced Solid Tumors
Cancer, Solid Tumors
Phase I Study of TAS-106 in Combo With Carboplatin
The goal of this clinical research study is to find the highest safe dose of the combination of TAS-106 and carboplatin that can be given to patients with advanced cancer or cancer that has spread.
- Trial name
- NCT00752011
- Testing
- TAS-106, Carboplatin
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Malignant Solid Tumor, Malignant Pleural Effusion
A Study of MT027 in Patients with Pleural Malignant Tumors
This is a phase I open label, single-arm, dose-escalation study to evaluate the feasibility, safety, tolerability, PK/PD, and to determine RP2D of MT027 via an locoregional delivery in subjects with pleural malignant tumors, who…
- Conditions
- Advanced Malignant Solid Tumor, Malignant Pleural Effusion, Pleura Carcinoma, Pleural Mesothelioma
- Trial name
- NCT06726564
- Testing
- MT027 cells suspension
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Suzhou Maximum Bio-tech Co., Ltd.
Breast Cancer, Ovarian Cancer
FPA150 in Patients With Advanced Solid Tumors
This is a multi-center study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of FPA150, an anti-B7H4 antibody alone or in combination with pembrolizumab an anti-PD1…
- Conditions
- Breast Cancer, Ovarian Cancer, Endometrial Cancer, Advanced Solid Tumors
- Trial name
- FPA150-001 (NCT03514121)
- Testing
- FPA150, Pembrolizumab
- Where
- 18 sites in United States, South Korea
- Volunteers
- 95 people
- Sponsor
- Five Prime Therapeutics, Inc.
Neoplasms, Triple-Negative Breast Cancer
A Study Of PF-06647263 In Patients With Advanced Solid Tumors
To assess the safety and tolerability at increasing dose levels of PF-06647263 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
- Trial name
- NCT02078752
- Testing
- PF-06647263
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Pfizer
Advanced Solid Tumors
This Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid Tumors
This is the first study using PF-03758309, an oral compound, in patients with advanced solid tumors. In this study different doses of PF-03758309 will be administered to different groups of patients.
- Trial name
- NCT00932126
- Testing
- PF-03758309
- Where
- 3 sites in United States, Australia
- Volunteers
- 35 people
- Sponsor
- Pfizer
Solid Tumor, Non-Hodgkin Lymphoma
Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma
This is a Phase 1, open-label, dose-escalation, single-center study of ADG106 in subjects with advanced or metastatic solid tumors and/or relapsed/ refractory non-Hodgkin lymphoma.
- Trial name
- NCT03802955
- Testing
- ADG106
- Where
- 2 sites in China
- Volunteers
- 62 people
- Sponsor
- Adagene (Suzhou) Limited
Advanced Solid Tumors
A Dose-finding Study of Dalotuzumab in Subjects With Advanced Solid Tumors (MK-0646-002)
The study determined the recommended Phase 2 loading and maintenance doses and dose schedules for administering dalotuzumab using dose-limiting toxicities (DLTs) observed during the entire treatment period (Up to 18 months).
- Trial name
- NCT00635778
- Testing
- dalotuzumab
- Volunteers
- 50 people
- Sponsor
- Merck Sharp & Dohme LLC
Neoplasms
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Determine the safety, tolerability, and maximum tolerated dose (MTD) of IV administered VIP236 as monotherapy in patients with advanced solid tumor cancer
- Trial name
- NCT05712889
- Testing
- VIP236 (Q3W), VIP236 (Q2W)
- Where
- 6 sites in United States, Australia
- Volunteers
- 29 people
- Sponsor
- Vincerx Pharma, Inc.
Solid Tumour
Study of PHA-848125AC in Adult Patients With Advanced/Metastatic Solid Tumors
The purpose of this open-label, multi center, Phase I study was to determine the safety profile of the oral compound PHA-848125AC administered according to two different schedules of administrations to advanced/metastatic solid…
- Trial name
- NCT01300468
- Testing
- PHA-848125AC
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Nerviano Medical Sciences
Advanced Malignant Solid Neoplasm, Estrogen Receptor Positive
Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients
This phase I trial studies the side effects and best dose of everolimus and trastuzumab when given together with letrozole in treating patients with hormone receptor-positive and human epidermal growth factor (EGF) receptor 2…
- Conditions
- Advanced Malignant Solid Neoplasm, Estrogen Receptor Positive, HER2/Neu Positive, Postmenopausal
- Trial name
- NCT02152943
- Testing
- Everolimus, Laboratory Biomarker Analysis, Letrozole
- Where
- 5 sites in United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Solid Tumor, Metastatic Solid Tumor
A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas
This is a First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas.
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Mature B-cell Non-Hodgkin Lymphoma
- Trial name
- NCT05490043
- Testing
- ATG-101
- Where
- 4 sites in China
- Volunteers
- 33 people
- Sponsor
- Antengene (Hangzhou) Biologics Co., Ltd.
Advanced Solid Tumors
Phase 1 Study of the Effect of Ketoconazole on the PK of Multiple Doses of Cediranib in Patients With Solid Tumours
Phase I, open study to assess the effect of ketoconazole, a marketed drug, on the way the body handles the experimental drug cediranib, in patients with advanced cancer.
- Trial name
- NCT00750425
- Testing
- cediranib (RECENTIN TM, AZD2171)
- Where
- 5 sites in Canada, Denmark
- Volunteers
- 46 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer, Solid Tumor
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors
This study is an open-label, multicenter, dose-escalation and cohort expansion phase I clinical study to evaluate the safety, tolerability, pharmacokinetics characteristics or preliminary efficacy and antitumor activity in…
- Trial name
- NCT06612840
- Testing
- GNC-077
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, HNSCC for Phase 2 Dose Expansion
Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors
This was an open-label, multicenter, nonrandomized Phase 1 and 2 clinical trial evaluating various combinations of surzebiclimab (BGB-A425) and/or alcestobart (LBL-007) with tislelizumab.
- Conditions
- Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, HNSCC for Phase 2 Dose Expansion, NSCLC for Phase 2 Dose Expansion
- Trial name
- NCT03744468
- Testing
- Surzebiclimab, Tislelizumab, Alcestobart
- Where
- 40 sites in United States, Australia and 4 more
- Volunteers
- 147 people
- Sponsor
- BeiGene
Advanced Solid Tumor
Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients
Phase 1, single-arm, open-label, dose escalating and expansion clinical trial to evaluate the safety, tolerability, pharmacokinetic and preliminary efficacy of Lurbinectedin (PM01183) for injection in patients with advanced solid…
- Trial name
- NCT04638491
- Testing
- Lurbinectedin for injection
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Luye Pharma Group Ltd.
Solid Malignancies
Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase
This Phase 1, open label, single centre, non-randomised study in patients with advanced solid malignancies consists of two parts: 1.
- Trial name
- 14C (NCT02640755)
- Testing
- [14C]AZD2014, Multiple dose AZD2014, Fulvestrant
- Where
- United Kingdom
- Volunteers
- 4 people
- Sponsor
- AstraZeneca
Advanced Solid Tumor
Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.
Open-label, two parallel arm, multicenter, Phase 1 dose-escalation study to evaluate the safety and tolerability of OMTX705, both as monotherapy or in combination with pembrolizumab (Part 1) or tislelizumab (Part 2) in the…
- Trial name
- NCT05547321
- Testing
- OMTX705, Pembrolizumab, Tislelizumab (BGB-A317)
- Where
- 9 sites in United States, Spain
- Volunteers
- 150 people
- Sponsor
- Oncomatryx Biopharma S.L.
Advanced or Metastatic Solid Tumors
Phase I Clinical Study of Metatinib Tromethamine Tablet
Primary Objective: To evaluate the safety, tolerability and maximum tolerated dose (MTD) of daily oral administration of metatinib tromethamine in subjects with solid tumors; Investigate the influence of food on pharmacokinetic…
- Trial name
- NCT02004548
- Testing
- Metatinib Tromethamine
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Advanced Solid Tumors Cancer
Trial to Study the Safety, Pharmacokinetics and Preliminary Antitumour Activity of ODM-216 in Patients With Cancer
A Phase 1/2, Open-Label, First-in-Human Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumour Activity of ODM-216 in Participants With Advanced Solid Tumours
- Trial name
- BICIDES (NCT07805252)
- Testing
- ODM-216
- Where
- 7 sites in Spain
- Volunteers
- 195 people
- Sponsor
- Orion Corporation, Orion Pharma
Malignant Solid Tumours
PDM08 Clinical Trial in Advanced Solid Tumors
This phase I study in adult patients with advanced solid tumours is designed to evaluate toxicity, drug exposure (pharmacokinetics) and drug action (pharmacodynamics) of a new molecule, PDM08, administered twice a week cycles of…
- Trial name
- NCT01380249
- Testing
- PDM08
- Where
- Spain
- Volunteers
- 22 people
- Sponsor
- Prodimed S.A.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.